Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer
Susana García‐Recio(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), Joel S. Parker(University of North Carolina at Chapel Hill), Gina N. Duronio(University of North Carolina at Chapel Hill), Aleix Prat(Hospital Clínic de Barcelona), Cheng Fan(University of North Carolina at Chapel Hill), Marni B. Siegel(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k